

## THERMAL BEHAVIOR OF ORTHORHOMBIC POLYMORPHS I AND II OF SPIRONOLACTONE

P. Espeau<sup>1\*</sup>, B. Nicolai<sup>1</sup>, R. Céolin<sup>1</sup>, M.-A. Perrin<sup>1</sup>, L. Zaske<sup>1</sup>, J. Giovannini<sup>2</sup> and F. Leveiller<sup>2</sup>

<sup>1</sup>Laboratoire de Chimie Physique, EA 4066, Faculté de Pharmacie, 4 av. de l’Observatoire 75006 Paris, France

<sup>2</sup>AstraZeneca R and D, 221 87 Lund, Sweden

Investigation into the thermal behavior of orthorhombic Forms I and II of spironolactone, by means of differential scanning calorimetry and high-resolution X-ray powder diffraction, showed that Form I melts then recrystallizes into Form II at 373–393 K, *i.e.* in the temperature range within which high resolution X-ray powder diffraction showed that Form I transforms into Form II. Refinements of the lattice parameters of the two forms indicated that Form I is denser than Form II in the range from 298 K up to the temperature at which it melts.

**Keywords:** differential scanning calorimetry, spironolactone, polymorphism, X-ray powder diffraction

### Introduction

The crystal structures of two orthorhombic polymorphs of spironolactone (Forms I and II) were solved previously [1, 2]. Form II, the usual commercial phase, was found to melt at 483 K ( $\Delta_{\text{fus}}H(\text{II})=22.1 \text{ kJ mol}^{-1}$ ) and Form I was assumed to melt at 478 K ( $\Delta_{\text{fus}}H(\text{I})=20.0 \text{ kJ mol}^{-1}$ ) according to previous differential scanning calorimetry (DSC) measurements [3]. However, X-ray powder diffraction studies as a function of temperature showed that Form I transforms into Form II at about 393 K [4], *i.e.* possibly conflicting with previous results [3]. In order to check whether the transition of Form I into Form II involves only crystalline phases, new investigations combining DSC measurements and X-ray powder diffraction studies as a function of the temperature were performed. Results are presented in the following.

### Material and methods

A spironolactone sample of medicinal grade Form II from Roussel was used as such after checking its crystallographic purity. To determine the heat of the I–II transition, crystals of Form I were grown by slow desolvation of the ethanol solvate at room temperature.

DSC runs were performed at various rates (5 to 15 K min<sup>-1</sup>) by means of a DSC 822<sup>e</sup> thermal analyzer from Mettler-Toledo. Indium was used as a reference for calibrating temperatures and enthalpy changes. Samples were weighed with a microbalance sensitive to 0.01 mg then closed in aluminum pans.


X-ray powder diffraction (XRPD) data collection was carried out on solids placed in concave alu-

minum holders under nitrogen flow (250 mL min<sup>-1</sup>) with a Siemens–Bruker D5000 diffractometer (parafocusing Bragg–Brentano ( $\theta$ – $\theta$ )-type geometry) equipped with an Anton-Paar TTK heating chamber. The parallelism of the  $K\bar{\alpha}$  (Fe-filtered) incident beam ( $\lambda_{\text{CoK}_{\alpha_1}}=1.7890 \text{ \AA}$  and  $\lambda_{\text{CoK}_{\alpha_2}}=1.7929 \text{ \AA}$ ) was improved by means of Soller slits. A 1-mm collimator was used to reduce the diffusion from the anticathode (40 kV, 30 mA) to the diffracting area, which was kept constant by means of variable-divergence slits. The XRPD profiles were recorded with a Braun 50-M multichannel linear detector (10°(20°)-wide detection window) at a 0.05 (20°) s<sup>-1</sup> rate in the 1.5–50° (20°)-range. Data were collected isothermally at 5 K intervals, with a heating rate in between data collection of 3 K min<sup>-1</sup>, and lattice parameters values were refined using the FullProf suite [5].


### Results and discussion

DSC runs on Form I crystals (Fig. 1) showed that transition I–II is not an enantiotropism-related solid-solid transition since an endothermic-exothermic sequence of peaks was recorded from about 373 to 393 K upon heating at 5 and 15 K min<sup>-1</sup> rates, reminiscent of the thermal behavior previously reported by Florence and Salole [6]. It was concluded that the I–II transition occurs as a melting-recrystallisation process that was not ‘seen’ through previous X-ray diffraction experiments [4]. Such an outcome was confirmed by visual examination of the process using a Mettler FP51 hot stage (see insets in Fig. 1), as well as

\* Author for correspondence: Philippe.Espeau@univ-paris5.fr



**Fig. 1** DSC curves for spironolactone A – Form II and B – Form I. The endo-exothermic sequence (peaks ‘a’ and ‘b’) indicates that the fusion of Form I precedes the recrystallisation of the melt into Form II, as shown by visual examination of the process by means of a hot stage (see insets in which the arrows indicate the temperatures at which the photographs were taken)



**Fig. 2** High resolution X-ray diffraction profiles recorded as a function of the temperature starting with a sample of spironolactone Form I (interval between profiles: 10°). In spite of preferred orientations, the transformation of Form I into Form II is visible in the temperature range indicated by the horizontal arrows (about 373–393 K)

by an X-ray diffraction control of the recrystallized phase cooled from 423 K to room temperature.

The onset temperature of the melting of Form II, recorded at 480 K, and the related heat of fusion,  $\Delta_{\text{fus}}H(\text{II})=22.9 \text{ kJ mol}^{-1}$ , were found to be close to previous determination [3].

As far as the enthalpy change associated with the I to II transition is concerned, summing over the whole endo-exothermic effect gave values near 0 ( $0\pm0.8 \text{ kJ mol}^{-1}$ ), thus preventing from unambiguous conclusion as to the endo- or exothermic character of the transition. Nevertheless, such a result indicates that the melting enthalpy of Form I should be close to that of Form II at the temperature at which the event occurs.

X-ray powder diffraction profiles of Forms I and II recorded from 298 to 493 K showed the same results as those previously found with regard to the I-II transition [4]. The thermal behavior of Form I as a function of the temperature and its transition into Form II are shown in Fig. 2. In addition, specific volumes calculated from refined lattice parameters indicated that Form I is the denser phase in the T-range investigated. It came to:  $v(\text{I})/\text{cm}^3 \text{ g}^{-1}=0.75047+(0.00012983 \cdot T/\text{K})$  ( $r^2=0.9917$ ) and  $v(\text{II})/\text{cm}^3 \text{ g}^{-1}=0.75405+(0.00015647 \cdot T/\text{K})$  ( $r^2=0.9978$ ), indicating that the dependence of the specific volumes of these polymorphs on the temperature is virtually linear.

## Conclusions

As far as the thermal behavior of Forms I and II are concerned, these studies performed using well-characterized samples unambiguously showed that Form I cannot melt at 478 K since it does at about 373–393 K.

It is also worth noting that the value for the melting enthalpy of Form II is smaller than the values usually found (33.3–50.0  $\text{kJ mol}^{-1}$ ) for a number of molecular drugs. This may be related to the lack of hydrogen bonds in orthorhombic packing, in which molecules are held together by van der Waals interactions [1, 2]. Nevertheless, this does not explain why so great a difference in the melting temperatures is found.

With regards to the relative stabilities of these two polymorphs, it may provisionally be suggested that Form I is less stable than Form II at temperatures greater than 298 K, since it melts at a temperature far smaller than that of Form II, although it was the first phase isolated and characterized (thus erroneously named Form I) [1, 6].

## References

- 1 O. Dideberg and L. Dupont, *Acta Cryst., B* 28 (1972) 3014.
- 2 V. Agafonov, B. Legendre and N. Rodier, *Acta Cryst., C* 45 (1989) 1661.
- 3 V. Agafonov, B. Legendre, N. Rodier, D. Wouessidjewe and J.-M. Cense, *J. Pharm. Sci.*, 80 (1991) 181.
- 4 W. Liebenberg, E. C. van Tonder, T. G. Dekker and M. M. de Villiers, *Pharmazie*, 58 (2003) 6.
- 5 J. Rodriguez-Carvajal, ‘FULLPROF: A Program for Rietveld Refinement and Pattern Matching Analysis’. Abstract of the Satellite Meeting on Powder Diffraction of the XV Congress of the IUCR, p. 127, Toulouse, France (1990).
- 6 A. T. Florence and E. G. Salole, *J. Pharm. Pharmacol.*, 28 (1976) 637.